Late cytomegalovirus polyradiculopathy following haploidentical CD34+- selected hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 33, Issue 2, 2004, Pages 243-245

  Zeiser, R ^a,b   Grullich C ^a   Bertz, H ^a   Pantazis, G ^a   Hufert, F T ^a   Bley, T A ^a   Finke, J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

CD34+ selected; Cytomegalovirus; Haploidentical; Hematopoietic stem cell transplantation; Polyradiculopathy

Indexed keywords

ANTIVIRUS AGENT; CD34 ANTIGEN; FLUDARABINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; MELPHALAN; THIOTEPA; THYMOCYTE ANTIBODY; VALACICLOVIR; VALGANCICLOVIR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOPSY; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG RESISTANCE; HAPLOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RADICULOPATHY; TREATMENT FAILURE; VIRUS ENCEPHALITIS;

ACUTE DISEASE; ANTIGENS, CD34; CYTOMEGALOVIRUS INFECTIONS; FATAL OUTCOME; HAPLOIDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; POLYRADICULOPATHY;

EID: 0842345585     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704311     Document Type: Article

References (11)

1. Boeckh M, Riddel SR, Cunninham T et al. Increased incidence of late CMV disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMV specific T cell responses. Blood 1996; 88 (Suppl 1): 302a.
2. Seo SK, Regan A, Cihlar T et al. Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance. Clin Infect Dis 2001; 33: 105-108.
3. Wolf DG, Lurain NS, Zuckerman T et al. Emerge of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood 2003; 101: 463-465.
4. Anders HJ, Goebel FD. Cytomegalovirus polyradiculopathy in patients with AIDS. Clin Infect Dis 1998; 27: 345-352.
5. Cesaro S, Gazzola MV, Marson P et al. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis. Am J Hematol 2003; 72: 143-146.
6. Meyer-König U, Serr A, Hufert FT et al. Laboratory diagnosis of HCMV-related disease in renal transplant patients - pp65 antigen detection vs nested PCR. Clin Diag Virol 1995; 3: 49.
7. Michel D, Höhn S, Haller T et al. Aciclovir selects for ganciclovir-cross-resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein. J Med Virol 2001; 65: 70-76.
8. Arribas JR, Storch GA, Clifford DB et al. Cytomegalovirus encephalitis. Ann Intern Med 1996; 125: 577-587.
9. Li CR, Greenberg PD, Gilbert MJ et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-1979.
10. Boeckh M, Leisenring W, Riddell SR et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101: 407-414.
11. Fletcher C, Sawchuk R, Chinnock B et al. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 1986; 40: 281-286.